Optimizing Pulmonology Prior Authorizations with Magellan Healthcare

Klivira delivers intelligent automation for pulmonology prior authorizations, specifically designed to navigate the utilization management requirements of Magellan Healthcare.

Revenue cycle directors and prior authorization coordinators in pulmonology face unique challenges when managing approvals with Centene-owned Magellan Healthcare. The complexity of specialty drugs, durable medical equipment, and advanced therapies demands a precise, evidence-based approach to avoid delays and denials. Klivira integrates seamlessly to streamline this critical workflow.

Navigating Magellan Healthcare's Utilization Management for Pulmonology

Magellan Healthcare, a Centene-owned entity, plays a significant role in utilization management, including pharmacy benefits and medical necessity reviews. For pulmonology practices, this translates to specific requirements for high-cost medications and durable medical equipment, necessitating a clear understanding of their review criteria to ensure timely patient access to care.

Common PA Triggers in Pulmonology for Magellan Healthcare

Asthma biologics, including omalizumab (Xolair), mepolizumab (Nucala), dupilumab (Dupixent), benralizumab (Fasenra), and tezepelumab (Tezspire).
IPF antifibrotics such as pirfenidone (Esbriet) and nintedanib (Ofev).
Home oxygen therapy and BiPAP/CPAP devices for respiratory support.
Select COPD specialty drugs and maintenance therapies requiring step-therapy documentation.
Lung transplant evaluations and associated immunosuppression regimens.

Clinical Documentation and Guideline Alignment for Magellan Reviews

Successful prior authorizations for pulmonology services with Magellan Healthcare hinge on submitting comprehensive clinical documentation that aligns with established guidelines. For asthma biologics, this often means demonstrating compliance with GINA guidelines, including eosinophil counts and documented trials of prior controller therapies. IPF antifibrotics typically require evidence supporting the diagnosis and failure of conservative therapies, consistent with relevant clinical standards like those from the ATS.

Streamlining EMR Data Exchange for Magellan Pulmonology PAs

Klivira's platform integrates with leading EMR systems to automate the extraction of critical clinical data required for Magellan Healthcare prior authorizations. This includes patient demographics, diagnosis codes, medication history, lab results (e.g., eosinophil counts), and relevant provider notes. By leveraging standards like SMART on FHIR, we ensure that necessary information is accurately and efficiently prepared for submission via electronic prior authorization (ePA) channels or the X12 278 transaction.

Mitigating Denial Risks with Klivira for Magellan Healthcare

Automated verification of step-therapy completion for asthma biologics, a frequent denial reason when payer requirements for high-dose ICS-LABA trials are not met.
Proactive flagging of insufficient eosinophil-count thresholds for IL-5-targeting biologics, ensuring all criteria are met before submission.
Structured documentation workflows to demonstrate the inadequacy of conservative therapy for IPF antifibrotics.
Real-time alerts for missing or incomplete clinical data, reducing resubmission rates.

Klivira's Intelligent Automation for Pulmonology Workflows

Klivira provides GINA/GOLD/ATS-aware step-therapy logic and automates the collection and presentation of eosinophil-count documentation. Our system is designed to accelerate the initial and re-authorization workflows for critical asthma biologics and other high-volume pulmonology PAs, ensuring that your team can focus on patient care rather than manual administrative tasks.

Frequently asked questions

What specific EMR data points are crucial for pulmonology PAs submitted to Magellan Healthcare?

Key data points include patient demographics, ICD-10 codes for respiratory conditions, medication lists (especially for controller therapies and biologics), lab results like eosinophil counts, pulmonary function test results, and documentation of prior treatment failures or exacerbation history, aligning with GINA, GOLD, or ATS guidelines.

How does Klivira handle Magellan's step-therapy requirements for asthma biologics?

Klivira incorporates GINA-aware step-therapy logic, automatically identifying and documenting whether a patient has met the required trials of inhaled corticosteroids and LABAs. Our system helps compile the necessary evidence to demonstrate compliance with Magellan's specific step-therapy policies, minimizing rejections.

Can Klivira assist with prior authorizations for durable medical equipment like home oxygen or BiPAP for Magellan members?

Yes, Klivira supports the prior authorization process for DME common in pulmonology, including home oxygen and BiPAP devices. Our platform helps gather the required medical necessity documentation, such as oxygen saturation levels, sleep study results, and physician orders, streamlining submission to Magellan Healthcare.

What are common reasons for denial of IPF antifibrotics by Magellan Healthcare, and how does Klivira address them?

Common denials for IPF antifibrotics often stem from insufficient documentation of diagnosis or failure to demonstrate the inadequacy of conservative therapy. Klivira structures the documentation workflow to ensure all clinical criteria, consistent with ATS guidelines, are met and clearly presented to Magellan, reducing the likelihood of denial.

Does Klivira integrate directly with Magellan's specific payer portals or use standard ePA channels?

Klivira connects with payers, including Magellan Healthcare, through a combination of standard ePA channels like X12 278 and direct integrations where available. Our goal is to ensure efficient and reliable submission of prior authorization requests, regardless of the specific payer's preferred intake method.